<DOC>
	<DOCNO>NCT02242747</DOCNO>
	<brief_summary>Background : 5 % 5-fluorouracil cream ( 5-FU ) well-established treatment actinic keratosis ( AK ) ingenol mebutate gel ( IMB ) new topical field therapy . Objective : To compare tolerability safety IMB 5-FU treatment facial AKs . Methods : Open-label , prospective , randomize , control clinical trial 100 patient AKs within 25-cm2 contiguous field face . IMB apply daily three consecutive day . 5-FU applied twice day four week . Treatment effect evaluate baseline day 2 , 3 , 4 , 8 , 15 , 22 , 29 , 36 43 , consider ITT population .</brief_summary>
	<brief_title>Safety Tolerability Study Ingenol Mebutate Compared 5-FU Treat Facial Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>age least 18 year presence four eight clinically typical , visible , discrete AKs within 25cm2 contiguous field face ( cheek forehead region ) Women childbearing potential use effective birth control confirm negative urine pregnancy test prior trial treatment . target treatment area within 5 cm incompletely heal wound within 10 cm suspect basalcell squamouscell carcinoma receive previous treatment ingenol mebutate gel face scalp ( previous treatment trunk extremity acceptable ) select treatment area hyperkeratotic lesion cutaneous horn recalcitrant disease ( lesion respond cryotherapy two previous occasion ) history evidence skin condition would interfere evaluation trial medication ( e.g. , eczema , unstable psoriasis , xeroderma pigmentosum ) anticipate need hospitalization outpatient surgery first 15 day first trial medication application know sensitivity allergy ingredient ingenol mebutate gel 5FU presence sunburn within target treatment area ; current enrolment participation interventional clinical trial within 30 day entry trial woman breastfeed recent use medication treatment could interfere evaluation target area , topical medication ( e.g . steroid , keratolytics , immunomodulators ) , artificial tanner , immunomodulators , cytotoxic drug interferon /interferon inducer , phototherapy , systemic retinoids , biologic/monoclonal antibody drug , therapy AKs within eight week prior first visit trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>actinic keratosis</keyword>
	<keyword>field cancerization</keyword>
	<keyword>ingenol mebutate</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
</DOC>